Haleon plc (LON:HLN – Get Free Report)’s share price hit a new 52-week low during trading on Thursday. The company traded as low as GBX 315.20 and last traded at GBX 315.49, with a volume of 1,008,922,813 shares changing hands. The stock had previously closed at GBX 374.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on HLN. Deutsche Bank Aktiengesellschaft cut their price target on shares of Haleon from GBX 335 to GBX 320 and set a “sell” rating on the stock in a research note on Wednesday, September 9th. Jefferies Financial Group reissued a “buy” rating and set a GBX 400 price target on shares of Haleon in a research report on Friday, July 31st. Berenberg Bank raised their price objective on shares of Haleon from GBX 512 to GBX 514 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Finally, Royal Bank Of Canada lifted their price objective on shares of Haleon from GBX 370 to GBX 390 and gave the company a “sector perform” rating in a report on Tuesday, August 11th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of GBX 387.80.
View Our Latest Stock Analysis on Haleon
Haleon Stock Down 15.6%
The company has a debt-to-equity ratio of 50.38, a quick ratio of 0.93 and a current ratio of 0.69. The company has a market cap of £27.75 billion, a price-to-earnings ratio of 17.43, a price-to-earnings-growth ratio of 1.49 and a beta of 0.24. The business has a 50-day simple moving average of GBX 354.60 and a 200-day simple moving average of GBX 360.88.
Haleon (LON:HLN – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The company reported GBX 8.60 EPS for the quarter. Haleon had a return on equity of 9.89% and a net margin of 14.55%. On average, equities analysts anticipate that Haleon plc will post 19.50 earnings per share for the current fiscal year.
Haleon Company Profile
Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.
Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.
Recommended Stories
- Five stocks we like better than Haleon
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.
